Endpoint
HOMA-IR
CAT:outcome/homa-irreported in index33 findings from 23 compounds
What moved it
How to read these marks33 findings · 23 compounds · 12 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| berberine | down | 5 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| curcumin | down | 3 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| all-cis-5,8,11,14,17-icosapentaenoic acid | down | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| melatonin | no effect 1 · down 1 | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| bisphenol A | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| lipoic acid | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| myo-inositol | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| NMN zwitterion | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| pravastatin | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Vitis vinifera | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Zn(2+) | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| α-tocopherol | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| choline | no effect | 1 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
| chromium(3+) | no effect | 1 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
| L-citrulline | no effect | 1 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
| coenzyme Q10 | no effect 1 · down 1 | 2 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| resveratrol | down 1 · no effect 1 | 2 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| (-)-epigallocatechin 3-gallate | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| L-arginine | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| Moringa oleifera | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| quercetin | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| sucralose | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| ursolic acid | down | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
21 findings
all-cis-5,8,11,14,17-icosapentaenoic acid — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Insulin resistance (HOMA-IR) significantly decreased in the EPA-rich fish oil than the controls (p = 0.001).”
Quoted verbatim from Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.. - Study
- RCT
- Participants
- 24
- Duration
- 3 weeks
- Dose
- 1.5 g/day EPA as EPA-rich fish oil capsules (500 mg EPA per capsule, three times daily with meals)
- Population
- Hospitalised adults aged 18-65 with non-severe burns covering less than 20% of total body surface area, able to take more than 90% of their daily calorie requirement by mouth, without diabetes, organ failure, cancer or immune disorder; both the EPA arm and the control arm also received 600 mg/day DHA.
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.2025PMID:41254027Permalink
myo-inositol — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“We found significant reductions in HOMA-IR (MD −0.6; 95% CI −1.2 to 0.0) and levels of insulin (MD −2.69; 95% CI −5.26 to −0.18) in the intervention group versus control.”
Quoted verbatim from Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.. - Study
- RCT
- Dose
- 2 g myo-inositol twice daily with 200 µg folic acid twice daily, until delivery
- Population
- Multiethnic pregnant women at high risk of gestational diabetes, 12+0 to 15+6 weeks' gestation at recruitment, UK; both arms took 200 µg folic acid twice daily, the control arm in a xylitol placebo powder; HOMA-IR measured at 28 weeks' gestation
Effect -0.6 mean difference, 95% CI -1.2 to 0
Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.2022PMID:35277398Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“The results showed that curcumin reduced HOMA-IR compared with placebo [WMD = -0.28, 95% CI (-0.36, -0.20), P < 0.00001].”
Quoted verbatim from Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.. - Study
- meta-analysis
- Participants
- 343
- Population
- adults with non-alcoholic fatty liver disease
Effect -0.28 mean difference, 95% CI -0.36 to -0.2
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.2022PMID:36159792Permalink
Zn(2+) — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Zinc supplementation significantly reduced HOMA‐IR (MD = −1.10; 95% CI −2.05 to −0.15; p = 0.02), with considerable heterogeneity (I 2 = 79%).”
Quoted verbatim from Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Adults and children with type 1 or type 2 diabetes, gestational diabetes or prediabetes in 18 pooled RCTs of zinc supplementation against placebo or standard care
Effect -1.1 mean difference, 95% CI -2.05 to -0.15
Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42594341Permalink
curcumin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“The means of HOMA-IR of the curcumin-treated group were lower than those of placebo group at all follow-up visits (3, 6, and 9 months).”
Quoted verbatim from Curcumin extract for prevention of type 2 diabetes.. - Study
- RCT
- Duration
- 9 months
- Dose
- curcumin extract capsules, 250 mg curcuminoids per capsule, 6 capsules/day (1500 mg/day) for 9 months
- Population
- adults with prediabetes
Curcumin extract for prevention of type 2 diabetes.2012PMID:22773702Industry fundedPermalink
berberine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Improved insulin resistance was assessed by lowering FINS (MD = -2.05, 95% CI (-2.62, -1.48)), HOMA-IR (MD = -0.71, 95% CI (-1.03, -0.39)), and BMI (MD = -1.07, 95% CI (-1.76, -0.37)).”
Quoted verbatim from The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes mellitus
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2021PMID:34956436Permalink
Show the remaining 15
Vitis vinifera — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Also, the between-group analysis showed that the average changes in insulin serum levels and HOMA-IR and HOMA-β indices in the intervention group with GSE were significantly lower than the control group (0.97 ± 0.52 vs. 0.90 ± 0.03, p = 0.04; 57.80 ± 21.16 vs. 53.97 ± 11.14, p = 0.04).”
Quoted verbatim from The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.. - Study
- RCT
- Dose
- two 260 mg grape seed extract tablets daily (520 mg/day) for 2 months
- Population
- Adults aged 20-60 with non-alcoholic fatty liver disease (moderate to severe steatosis on ultrasound), BMI 25-35, in a double-blind placebo-controlled trial
The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.2024PMID:38755622Permalink
berberine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“BBR supplementation significantly decreased HOMA-IR compared to placebo (WMD = −1.04; 95%CI, −1.55 to −0.52; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -1.04 mean difference, 95% CI -1.55 to -0.52
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
α-tocopherol — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Combining results of these studies revealed that vitamin E intake reduced HOMA-IR in diabetic patients (MD: -0.44, 95% CI: -0.82 to -0.05, P = 0.02, I2: 83.4%, P < 0.001).”
Quoted verbatim from Effect of vitamin E intake on glycemic control and insulin resistance in diabetic patients: an updated systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Adults with type 1 or type 2 diabetes, diabetic nephropathy or neuropathy; pooled randomised trials of vitamin E supplementation against a control group
Effect -0.44 mean difference, 95% CI -0.82 to -0.05
Effect of vitamin E intake on glycemic control and insulin resistance in diabetic patients: an updated systematic review and meta-analysis of randomized controlled trials.2023PMID:36800965Permalink
(-)-epigallocatechin 3-gallate — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The meta-analysis demonstrated that EGCG supplementation led to statistically significant, but modest, reductions in fasting blood glucose (FBG), HbA1c, and HOMA-IR.”
Quoted verbatim from Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Pooled across 41 randomized controlled trials of EGCG supplementation (meta-analysis of glycemic index and related parameters).
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40885603Permalink
coenzyme Q10 — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“CoQ10 alone or combined with vitamin E, and inositols were successful in decreasing HOMA-IR.”
Quoted verbatim from The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis.. - Study
- meta-analysis
- Population
- women with polycystic ovary syndrome
The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis.2021PMID:33988478Permalink
resveratrol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Resveratrol consumption significantly reduced fasting glucose, insulin, glycated hemoglobin, and insulin resistance (measured by using the homeostatic model assessment) levels in participants with diabetes.”
Quoted verbatim from Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials.. - Study
- meta-analysis
- Population
- participants with diabetes
Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials.2014PMID:24695890Permalink
melatonin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Our results showed that melatonin administration significantly reduced insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR), and increased the quantitative insulin sensitivity check index (QUICKI).”
Quoted verbatim from Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- adults, pooled across 8 RCTs (376 participants) of melatonin supplementation for insulin resistance
Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2021PMID:34496412Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Curcuminoids supplementation significantly decreased fasting blood glucose (p < 0.01), HbA1c (p = 0.031), and insulin resistance index (HOMA-IR) (p < 0.01) in type 2 diabetic patients.”
Quoted verbatim from Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.. - Study
- RCT
- Participants
- 100
- Duration
- 3 months
- Dose
- 300 mg/day
- Population
- overweight/obese adults with type 2 diabetes (BMI ≥ 24; fasting glucose ≥ 7.0 mmol/L or postprandial glucose ≥ 11.1 mmol/L)
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.2013PMID:22930403Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment ([Formula: see text]< 0.05).”
Quoted verbatim from Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.. - Study
- RCT
- Duration
- 3 months
- Population
- patients with schizophrenia, bipolar disorder, or schizoaffective psychosis with olanzapine-induced mild metabolic disorders, continuing olanzapine treatment (background, both arms)
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.2021PMID:34961418Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“As shown in Figure 1, BF treatment significantly increased plasma FINS, T-SOD, GSH-PX, and GLP-1 and reduced FBG, HOMA-IR, and plasma TG, TC, and GSP (all P < 0.05) in diabetic rats.”
Quoted verbatim from Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress.. - Study
- animal · not in humans
- Dose
- 500 mg/kg per day berberine fumarate by intragastric administration for 4 weeks
- Population
- Streptozotocin plus high-fat high-sucrose diet type 2 diabetic Sprague-Dawley rats given berberine fumarate versus distilled-water-treated diabetic rats
Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress.2018PMID:30662584Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Berberine lowered fasting glucose (-0.52 mmol/L, 95% CI -0.72 to -0.33; 18 studies, n = 1522), HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756), fasting insulin (-2.36 mU/L, 95% CI -3.64 to -1.08, 11 studies, n = 966), HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065), and 2-h postprandial glucose (-1.81 mmol/L, 95% CI -2.37 to -1.24, 4 studies, n = 501).”
Quoted verbatim from Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 1,065
- Population
- Adults in 20 randomized trials of berberine versus placebo, pooled across sexes and diabetes status
Effect -0.85 mean difference, 95% CI -1.16 to -0.53
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023PMID:37598753Permalink
ursolic acid — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Interleukin-15 (IL-15), Interleukin-6 (IL-6), Insulin, and HOMA-IR decreased significantly in the placebo and UA groups versus control, but the UA group significantly decreased compared with the placebo (p<0.05).”
Quoted verbatim from The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- capsule three times per day
- Population
- Obese women aged 50 to 70 years; moderate-to-high intensity resistance circuit training in both the UA and placebo arms
The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women.2021PMID:34528871Permalink
quercetin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The results showed that quercetin could effectively reduce HOMA-IR (MD=-4.13, 95% CI=[-5.82, -2.44], P < 0.00001), and the difference was statistically significant (Table 2).”
Quoted verbatim from Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis.. - Study
- animal · not in humans
- Population
- Meta-analysis of four studies in rodent models of polycystic ovary syndrome (DHEA- or letrozole-induced), quercetin versus model controls given no treatment or vehicle
Effect -4.13 mean difference, 95% CI -5.82 to -2.44
Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis.2024PMID:38637876Permalink
Moringa oleifera — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Improvement in insulin sensitivity was corroborated calculating HOMA-IR, which was significantly reduced in the HF + MO treated group compared to the HF group (p < 0.05; Figure 1E).”
Quoted verbatim from Moringa oleifera Improves MAFLD by Inducing Epigenetic Modifications.. - Study
- animal · not in humans
- Duration
- 8 weeks
- Dose
- 150 uL of 62.5 mg/mL extract daily by orogastric cannula, calculated as 290 mg/kg
- Population
- Male C57BL/6J mice fed a high-fat diet with high-sugar drinking water for 16 weeks (NASH model); extract given for the final 8 weeks, compared with untreated high-fat-diet mice
Moringa oleifera Improves MAFLD by Inducing Epigenetic Modifications.2022PMID:36296907Permalink
all-cis-5,8,11,14,17-icosapentaenoic acid — decreases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×1“The HOMA‐IR score was also lowered with EPA in the diet, relative to the mice consuming the HF diet.”
Quoted verbatim from Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner.. - Study
- animal · not in humans
- Duration
- 3 months
- Dose
- EPA ethyl esters (Cayman, at least 93% pure) in the high-fat diet, 2% of total energy; the paper states pure EPA ethyl esters were used, not mixtures with DHA
- Population
- Male C57BL/6J mice fed a high-fat diet (60% kcal from lard) for 15 weeks, with or without EPA ethyl esters
Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner.2020PMID:32579292Permalink
Measured, no effect detected
12 findings
lipoic acid — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
bisphenol A — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There were no statistical differences observed between BPA-50 and PL for HOMA-IR (P =.14), adipose-IR (P =.86), C-peptide to glucose ratio (P =.40), or FFAsuppression (P =.53) after treatment (Table 2).”
Quoted verbatim from Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial.. - Study
- RCT
- Duration
- 5 days
- Dose
- 50 ug/kg body weight daily on a vanilla wafer cookie, versus placebo cookie
- Population
- Healthy, sedentary, normal-weight adults (BMI 18.5 to 25 kg/m2, HbA1c under 5.7%); 5 days of energy-balanced diet low in bisphenols in both arms; secondary endpoint
Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial.2026PMID:41866316Permalink
NMN zwitterion — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The HOMA-IR showed no statistically significant differences for all NMN-treated groups as compared to placebo at day 60.”
Quoted verbatim from The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.. - Study
- RCT
- Duration
- 2 months
- Dose
- 300, 600 or 900 mg NMN once daily orally for 60 days
- Population
- Healthy middle-aged adults in a randomized, multicenter, double-blind, placebo-controlled, parallel-group trial; 300, 600 and 900 mg NMN groups each compared with placebo at day 60
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.2023PMID:36482258Permalink
pravastatin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use was not significantly associated with change in glucose metabolism measurements such as fasting glucose, fasting insulin, HOMA-IR (homeostasis model of assessment of insulin resistance) and HbA1c (hemoglobin A1c) from baseline to either week 6 or week 12 (table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline at week 6 and week 12
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
melatonin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“No significant effects of melatonin were found on HOMA-IR (WMD: 0.15, 95% CI: −0.18, 0.48), serum FI levels (WMD: 0.49 µIU/mL, 95% CI: −1.08, 2.05), or HbA1c (WMD: −0.22%, 95% CI: −0.66, 0.21).”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Population
- adults, pooled across 63 RCTs of melatonin supplementation across mixed clinical populations (including metabolic syndrome, chronic kidney disease, PCOS, COVID-19, multiple sclerosis, type 2 diabetes, and other conditions)
Effect 0.15 mean difference, 95% CI -0.18 to 0.48
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249Permalink
choline — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“There were no statistically significant differences in insulin sensitivity (Matsuda index) or insulin resistance (HOMA-IR) between the interventions in both the acute study and short-term study.”
Quoted verbatim from Gut microbiota-generated trimethylamine N-oxide from dietary choline and glucose homeostasis in humans.. - Study
- crossover
- Dose
- 1,000 mg/day choline bitartrate vs placebo (maltodextrin)
- Population
- Healthy, sedentary adults in two randomized, double-blind, placebo-controlled crossover studies (acute and 4-week), oral glucose tolerance test
Gut microbiota-generated trimethylamine N-oxide from dietary choline and glucose homeostasis in humans.2026PMID:42314769Permalink
Show the remaining 6
L-citrulline — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“Importantly, although we did not observe statistical significance in HOMA-IR, there was a decreasing trend in CIT and an increasing trend in placebo after 4 weeks.”
Quoted verbatim from Effects of L-Citrulline Supplementation on Endothelial Function, Arterial Stiffness, and Blood Glucose Level in the Fasted and Acute Hyperglycemic States in Middle-Aged and Older Adults with Type 2 Diabetes.. - Study
- crossover
- Participants
- 16
- Duration
- 4 weeks
- Dose
- 6 g/day L-citrulline as 750 mg capsules, four in the morning and four in the evening, for 4 weeks
- Population
- Middle-aged and older adults with type 2 diabetes, mean age 62 years, treated with oral hypoglycaemic drugs and/or insulin, none doing structured exercise.
Effects of L-Citrulline Supplementation on Endothelial Function, Arterial Stiffness, and Blood Glucose Level in the Fasted and Acute Hyperglycemic States in Middle-Aged and Older Adults with Type 2 Diabetes.2025PMID:41374029Permalink
chromium(3+) — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“No changes were observed in FPG, 2-hour plasma glucose levels, fasting or 2-hour post–oral glucose tolerance test insulin levels, or HOMA-IR as compared with placebo after 6 months of chromium use in either the 500-mcg and 1000-mcg arms (Table 2).”
Quoted verbatim from Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.. - Study
- crossover
- Duration
- 6 months
- Dose
- chromium picolinate 500 mcg or 1000 mcg daily
- Population
- Adults with impaired glucose tolerance, impaired fasting glucose or metabolic syndrome, without diabetes; modified cross-over, 6 months of chromium picolinate versus placebo
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.2011PMID:20634174Industry fundedPermalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation.”
Quoted verbatim from The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with chronic kidney disease (CKD)
The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2018PMID:30417782Permalink
resveratrol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“The results did not support that resveratrol intervention had favorable effects in altering high-density lipoprotein cholesterol (HDL-C), triglyceride (TAG), and homeostasis model assessment of insulin resistance (HOMA-IR).”
Quoted verbatim from Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults in randomized controlled trials of resveratrol supplementation
Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials.2018PMID:28933578Permalink
L-arginine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“However, the effects of l-arginine supplementation on HOMA-IR and HbA1c were not significant.”
Quoted verbatim from Effects of l-arginine supplementation on glycemic profile: Evidence from a systematic review and meta-analysis of clinical trials.. - Study
- meta-analysis
- Population
- Adults; pooled analysis of RCTs (search to 5 May 2018) of l-arginine supplementation on glycemic profile
Effects of l-arginine supplementation on glycemic profile: Evidence from a systematic review and meta-analysis of clinical trials.2020PMID:32561357Permalink
sucralose — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Sucralose did not significantly alter alpha diversity (Shannon index: SMD = -0.00; 95% CI -1.16 to 1.15; p = 0.99; I2 = 25.67%), fasting blood glucose (SMD = -0.04; 95% CI = -0.63 to 0.56; p = 0.88; I2 = 69.61%), and HOMA-IR (SMD = -0.13; 95% CI = -0.36 to 0.10; p = 0.212; I2 = 0.00%).”
Quoted verbatim from Effect of Sucralose Consumption on Gut Microbiota: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- healthy adults; pooled from randomized controlled trials of sucralose consumption
Effect -0.13 standardised mean difference, 95% CI -0.36 to 0.1
Effect of Sucralose Consumption on Gut Microbiota: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42794802Permalink
How it is measured
Homeostatic model assessment of insulin resistance, computed as fasting insulin multiplied by fasting glucose divided by the model constant — 22.5 for mU/L with mmol/L, 405 for microIU/mL with mg/dL. The constant and the input units are recorded with each finding.
Measured, not recorded
- Subject
- homa-ir
- Measurements
- 154 measurements
- Recorded as a finding
- No
Show what was measured
HOMA-IR
no effect, p = 0.88
HOMA-IR | 1.47 ± 0.97 | 1.36 ± 0.70 | 1.41 ± 0.93 | 1.36 ± 0.81 | 0.88
PMID:28562133 · both readings recorded this
HOMA-IR
decreases, HOMA-IR was evaluated in five studies, and this was reduced significantly by curcumin supplementation in three of those studies.
HOMA-IR was evaluated in five studies, and this was reduced significantly by curcumin supplementation in three of those studies.
PMID:34331688 · both readings recorded this
HOMA-IR
decreases, p = 0.001
Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively
PMID:18442638 · one of two readings recorded this
HOMA-IR
no effect
No changes were observed in FPG, 2-hour plasma glucose levels, fasting or 2-hour post–oral glucose tolerance test insulin levels, or HOMA-IR as compared with placebo after 6 months of chromium use in either the 500-mcg and 1000-mcg arms
PMID:20634174 · one of two readings recorded this
HOMA-IR
no effect
HOMA-IR | 2.36 | ± | 0.35 | 3.19 | ± | 0.24 | 1.35§ | ± | 0.11 | 1.29§§ | ± | 0.1
PMID:22509243 · one of two readings recorded this
HOMA-IR
decreases
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
HOMA-IR
decreases, p = 0.298
HOMA-IR | -0.26(-0.72~0.20) | -0.69(-1.18~-0.20) | -1.06(-1.51~-0.61) | 0.014 | 0.298
PMID:26252777 · one of two readings recorded this
HOMA-IR
no effect
HOMA-IR | -0.26(-0.72~0.20) | -0.69(-1.18~-0.20) | -1.06(-1.51~-0.61) | 0.014 | 0.298
PMID:26252777 · one of two readings recorded this
HOMA-IR
decreases, p = 0.014
HOMA-IR | -0.26(-0.72~0.20) | -0.69(-1.18~-0.20) | -1.06(-1.51~-0.61) | 0.014 | 0.298
PMID:26252777 · one of two readings recorded this
HOMA-IR
no effect, p = 0.39
HOMA-IR | 1.3±0.8 | 1.3±0.6 | 0.80 | 1.29±0.5 | 1.3±0.5 | 0.31 | 0.39
PMID:26406981 · one of two readings recorded this
HOMA-IR
decreases
demonstrated trend level reductions in HOMA-IR (homeostatic model assessment-insulin resistance; five studies; SMD=-0.57; 95% CI: -1.17 to 0.03; I2=88%)
PMID:27530471 · one of two readings recorded this
HOMA-IR
no effect, p = 0.21
HOMA-IR | 3.6 (2.4–4.1) | 2.8 (2.2–3.9) | 0.21 | 3.7 (2.5–5.0) | 3.4 (1.8–5.1) | 0.32
PMID:27629750 · one of two readings recorded this
HOMA-IR
no effect, p = 0.32
HOMA-IR | 3.6 (2.4–4.1) | 2.8 (2.2–3.9) | 0.21 | 3.7 (2.5–5.0) | 3.4 (1.8–5.1) | 0.32
PMID:27629750 · one of two readings recorded this
HOMA-IR
decreases, p = 0.03, n = 25
HOMA-IR | 2.03±0.26 | 2.39±0.24 | 1.97±0.29 | 1.77±0.27 | 0.03
PMID:29786471 · one of two readings recorded this
HOMA-IR
decreases
After the 8-week treatment course, the HOMA-IR value decreased significantly only in the coenzyme Q10 group, and the difference between the two groups was significant.
PMID:30151373 · one of two readings recorded this
HOMA-IR
no effect
Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation
PMID:30417782 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
BF treatment significantly increased plasma FINS, T-SOD, GSH-PX, and GLP-1 and reduced FBG, HOMA-IR, and plasma TG, TC, and GSP (all P < 0.05) in diabetic rats
PMID:30662584 · one of two readings recorded this
HOMA-IR
no effect, p = 0.92
HOMA-IR | 0.73 (0.59, 1.23) | 0.69 (0.51, 1.64) | 0.77 (0.52, 1.15) | 0.77 (0.49, 1.24) | 0.92
PMID:30795775 · one of two readings recorded this
HOMA-IR
decreases, p = 0.068
There was a tendency for decreased HOMA-IR index (p = 0.068; Mann–Whitney U test)
PMID:30959933 · one of two readings recorded this
HOMA-IR
no effect
Vitamin C supplementation alone or with Rutin significantly reduced the % change of FBG compared to controls but had no effect on HbA1c, FBG,TC, fasting insulin and HOMA-IR or oxidative stress in T2DMpatients
PMID:31987106 · one of two readings recorded this
HOMA-IR
decreases
The HOMA‐IR score was also lowered with EPA in the diet, relative to the mice consuming the HF diet
PMID:32579292 · one of two readings recorded this
HOMA-IR
decreases
For T2D outcomes, FBG and HOMA-IR showed significant improvements from low-dose zinc supplementation compared with placebo while HbA1c and HOMA-IR improved from high-dose supplementation compared with placebo
PMID:32722790 · one of two readings recorded this
HOMA-IR
decreases
Among the T2D risk factors, short-duration supplementation showed significant benefits for FBG and HOMA-IR
PMID:32722790 · one of two readings recorded this
HOMA-IR
decreases
For T2D outcomes, FBG and HOMA-IR showed significant improvements from low-dose zinc supplementation compared with placebo while HbA1c and HOMA-IR improved from high-dose supplementation compared with placebo
PMID:32722790 · one of two readings recorded this
HOMA-IR
no effect
HbA1c and HOMA-IR remained unchanged after sub-analysis by dose
PMID:33430470 · one of two readings recorded this
HOMA-IR
no effect
However, HOMA-IR exhibited no significant changes
PMID:33430470 · one of two readings recorded this
HOMA-IR
decreases, p = 0.04
effect size of HOMA-IR = −0.83, p = 0.04
PMID:33430470 · one of two readings recorded this
HOMA-IR
no effect
HbA1c and HOMA-IR did not show significant changes
PMID:33430470 · one of two readings recorded this
HOMA-IR
decreases
CoQ10 alone or combined with vitamin E, and inositols were successful in decreasing HOMA-IR
PMID:33988478 · one of two readings recorded this
HOMA-IR
decreases
CoQ10 alone or combined with vitamin E, and inositols were successful in decreasing HOMA-IR
PMID:33988478 · one of two readings recorded this
HOMA-IR
no effect
HOMA-IR did not show differences among groups
PMID:34054726 · one of two readings recorded this
HOMA-IR
decreases
HOMA-IR was lower in the LFD + Ex group compared to other groups, indicating that exercise only can increase insulin sensitivity
PMID:34054726 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0001
PCOS patients in atorvastatin therapy group had lower HOMA-IR value than those in placebo group (SMD −4.12, 95% CI −6.00 to -2.23, P <.0001)
PMID:34128863 · one of two readings recorded this
HOMA-IR
unclear
HOMA-IR [SMD0.5 = –0.64 (90% CrI: –1.82 to 0.47)
PMID:34333586 · one of two readings recorded this
HOMA-IR
decreases
decrease in HOMA-IR [SMD0.5 = –0.41 (90% CrI: –0.82 to –0.07)
PMID:34333586 · one of two readings recorded this
HOMA-IR
unclear
medium effect for decreased HOMA-IR [SMD0.5 = –0.63 (90% CrI: –1.98 to 0.65)
PMID:34333586 · one of two readings recorded this
HOMA-IR
decreases, p = 0.011
HOMA-IR (WMD: -0.40, 95% CI: -0.70, -0.09, p = 0.011)
PMID:34371867 · one of two readings recorded this
HOMA-IR
significantly different between groups; correlation with ingested aspartame r = 0.518, p = 0.04
Not recorded as a finding: sentence states a group difference and a correlation but no direction against control
Fasting plasma insulin levels failed to reach significance between the groups (P = 0·125), whereas HOMA-IR was significantly different between groups (P = 0·04) and strongly related to the amount of ingested aspartame (r = 0·518, P = 0·006), and thus insulin sensitivity was inversely related to aspartame intake.
PMID:34420538 · one of two readings recorded this
HOMA-IR
increases, p = 0.04
HOMA-IR | 7·41 | 11·10b | 17·73 | 10·26ab | 9·72 | 13·50b | 25·61 | 12·23a | 0·040
PMID:34420538 · one of two readings recorded this
HOMA-IR
no effect, p = 0.646
HOMA-IR | 7·41 | 11·10 | 17·23 | 14·96 | 11·32 | 20·38 | 17·56 | 16·85 | 0·646
PMID:34420538 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
Interleukin-15 (IL-15), Interleukin-6 (IL-6), Insulin, and HOMA-IR decreased significantly in the placebo and UA groups versus control, but the UA group significantly decreased compared with the placebo (p<0.05)
PMID:34528871 · one of two readings recorded this
HOMA-IR
decreases, n = 100
An oral intake of 300 mg/day glucosamine composition (curcumin 36.06%, dimethoxycurcumin 18.85%, bisdemethoxycurcumin 42.58%) for 12 weeks resulted in lower HbA1c and HOMA-IR levels compared to the placebo group in a randomized, double-blind placebo clinical study consisting of a total of 100 people
PMID:34885693 · one of two readings recorded this
HOMA-IR
decreases, decreased by 0.71, 95% CI [-1.03,-0.39]
the HOMA-IR level of the berberine group decreased by 0.71 (95% CI (−1.03, −0.39), P < 0.05, I2 = 96%, 95% CI (0.94, 0.97)).
PMID:34956436 · one of two readings recorded this
HOMA-IR
no effect
However, there were no beneficial effects on insulin, HOMA-IR, glycosylated hemoglobin (HbA1c), or fasting blood sugar (FBS)
PMID:34959992 · one of two readings recorded this
HOMA-IR
decreases, p = 0.067
serum insulin, QUICKI (p < 0.05), and HOMA-IR (p = 0.067) were significantly improved in the group treated with curcumin
PMID:34959992 · one of two readings recorded this
HOMA-IR
decreases, p = 0.031
HOMA-IR (p = 0.031)
PMID:34959992 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
(MD: −0.45, 95% CI: −0.90 to 0.00, p = 0.05, I2 = 0%)
PMID:35282455 · one of two readings recorded this
HOMA-IR
decreases
Vitamin E supplementation improves lipid profile, decreases insulin and HOMA-IR levels
PMID:35388031 · one of two readings recorded this
HOMA-IR
decreases, p = 0.01
at 3 months (−0.34 μIU/ml, −13.80%, p =.03 for FPI; −1.87, −31.60%, p <.01 for HOMA‐IR) and 6 months (−0.81 μIU/ml, −33.7%, p <.01 for FPI; −2.91, −51.40%, p <.01 for HOMA‐IR)
PMID:35912631 · one of two readings recorded this
HOMA-IR
decreases, p = 0.01
at 3 months (−0.34 μIU/ml, −13.80%, p =.03 for FPI; −1.87, −31.60%, p <.01 for HOMA‐IR) and 6 months (−0.81 μIU/ml, −33.7%, p <.01 for FPI; −2.91, −51.40%, p <.01 for HOMA‐IR)
PMID:35912631 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
The supplement also significantly lowered FPI levels after 9 months of treatment (−0.38 μIU/ml, −2.40%, p <.05) and HOMA‐IR at 6 months (−0.64, −15.90%, p <.05) and 9 months (−0.81, −20.10%, p <.001), whereas increased homeostatic model assessment of β‐cell function (HOMA‐B) (+12.47, +25.40%, p <.01) at 9 months compared to placebo
PMID:35912631 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
The supplement also significantly lowered FPI levels after 9 months of treatment (−0.38 μIU/ml, −2.40%, p <.05) and HOMA‐IR at 6 months (−0.64, −15.90%, p <.05) and 9 months (−0.81, −20.10%, p <.001), whereas increased homeostatic model assessment of β‐cell function (HOMA‐B) (+12.47, +25.40%, p <.01) at 9 months compared to placebo
PMID:35912631 · one of two readings recorded this
HOMA-IR
decreases, p = 0.01, n = 100
Na et al. reported that the administration of curcuminoids 300 mg/day or placebo in 100 overweight and obese T2DM subjects for a period of 3 months produced a significant reduction of FPG (−16.04 mg/dl, −10.90%, p <.01), HbA1c (−0.97%, −12.10%, p =.031), and HOMA‐IR (−1.35, −24.60%, p <.01)
PMID:35912631 · one of two readings recorded this
HOMA-IR
no effect, p = 0.06
The herbal medicine also slightly decreased HOMA‐IR without reaching statistical significance (−0.85, −35.00%, p =.06)
PMID:35912631 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
significant decrease in FBG, insulin, HbA1c, HOMO-IR, LDL-c, TG, VLDL, CHOL, LDL-c.HDL-c ratio, AIP, IL-6, and MDA and a significant increase in HDL-c, QUICKI index, BDNF, and TAC compared with the initial value (p for all <.05)
PMID:36101997 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
which was significantly reduced in the HF + MO treated group compared to the HF group (p < 0.05; Figure 1E)
PMID:36296907 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
BBR supplementation significantly decreased HOMA-IR compared to placebo (WMD = −1.04; 95%CI, −1.55 to −0.52; P < 0.001)
PMID:36313096 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
intervention dose ≤ 1 g/d (WMD = −1.37; 95%CI, −2.12 to −0.62; P < 0.001)
PMID:36313096 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
type 2 diabetes (WMD = −1.25; 95%CI, −1.62 to −0.88; P < 0.001)
PMID:36313096 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
trial duration > 8 weeks (WMD = −1.13; 95%CI, −1.40 to −0.86; P < 0.001)
PMID:36313096 · one of two readings recorded this
HOMA-IR
no effect, n = 80
The HOMA-IR showed no statistically significant differences for all NMN-treated groups as compared to placebo at day 60
PMID:36482258 · one of two readings recorded this
HOMA-IR
no effect, p = 0.065
Post-hoc between-group differences were significant for all groups (p = 0.0001) except for the TG and TSG (p = 0.065) (Table 2).
PMID:36678157 · one of two readings recorded this
HOMA-IR
no effect, p = 0.17
Levels of HOMA-IR decreased following 12 weeks of training in the SG (p = 0.0001), TG (p = 0.0001), and TSG (p = 0.0001), while the difference in HOMA-IR in the CG was not significant (p = 0.17).
PMID:36678157 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0001
Levels of HOMA-IR decreased following 12 weeks of training in the SG (p = 0.0001), TG (p = 0.0001), and TSG (p = 0.0001), while the difference in HOMA-IR in the CG was not significant (p = 0.17).
PMID:36678157 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0001
Levels of HOMA-IR decreased following 12 weeks of training in the SG (p = 0.0001), TG (p = 0.0001), and TSG (p = 0.0001), while the difference in HOMA-IR in the CG was not significant (p = 0.17).
PMID:36678157 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0001
Levels of HOMA-IR decreased following 12 weeks of training in the SG (p = 0.0001), TG (p = 0.0001), and TSG (p = 0.0001), while the difference in HOMA-IR in the CG was not significant (p = 0.17).
PMID:36678157 · one of two readings recorded this
HOMA-IR
Not recorded as a finding: One-sided negation ('does not significantly improve') does not establish no_effect (rule 1a).
This meta-analysis showed that selenium supplementation has a positive effect on TAC, and supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG.
PMID:36740666 · one of two readings recorded this
HOMA-IR
no effect
supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG
PMID:36740666 · one of two readings recorded this
HOMA-IR
no effect
Although HOMA-IR increased at the 180-day compared to the 90-day post-supplementation in the Novel Nutraceutical Supplement_(S) group there was no statiscal differences
PMID:36778595 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
and the difference was significant when compared to the placebo group (p < 0.05)
PMID:36800950 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
Serum levels of FBG (p = 0.001), HOMA-IR (p = 0.001), and urea (p = 0.017) were considerably lower in the ginger group compared to baseline
PMID:36800950 · one of two readings recorded this
HOMA-IR
no effect, p = 0.054
High | 7 | -0.95 (-1.93, 0.02) | 0.054 | 88.8 | < 0.001
PMID:36800965 · one of two readings recorded this
HOMA-IR
decreases, p = 0.02
MD: -0.44, 95% CI: -0.82 to -0.05, P = 0.02
PMID:36800965 · one of two readings recorded this
HOMA-IR
decreases, p = 0.02
< 500 | 7 | -0.98 (-1.83, -0.13) | 0.02 | 88.7 | < 0.001
PMID:36800965 · one of two readings recorded this
HOMA-IR
decreases, p = 0.01
α-tocopherol | 8 | -0.72 (-1.29, -0.15) | 0.01 | 87.5 | < 0.001
PMID:36800965 · one of two readings recorded this
HOMA-IR
no effect, p = 0.49
Tocoterienol | 1 | -0.10 (-0.39, 0.19) | 0.49 | 0 | -
PMID:36800965 · one of two readings recorded this
HOMA-IR
decreases, p = 0.01
MD: -0.30, 95% CI: -0.53 to -0.06, P = 0.01
PMID:36800965 · one of two readings recorded this
HOMA-IR
no effect, p = 0.15
< 10 | 4 | -0.18 (-0.43, 0.07) | 0.15 | 6.5 | 0.36
PMID:36800965 · one of two readings recorded this
HOMA-IR
no effect, p = 0.084
Low | 5 | -0.18 (-0.38, 0.02) | 0.084 | 0 | 0.518
PMID:36800965 · one of two readings recorded this
HOMA-IR
no effect, p = 0.08
Non-Western countries | 10 | -0.59 (-1.26, 0.08) | 0.08 | 84.6 | < 0.001
PMID:36800965 · one of two readings recorded this
HOMA-IR
no effect, p = 0.11
Western countries | 2 | -0.33 (-0.74, 0.08) | 0.11 | 86.0 | 0.007
PMID:36800965 · one of two readings recorded this
HOMA-IR
no effect, p = 0.63
Diabetic nephropathy | 1 | -0.20 (-1.03, 0.63) | 0.63 | 0 | -
PMID:36800965 · one of two readings recorded this
HOMA-IR
decreases, p = 0.02
T2DM | 11 | -0.47 (-0.88, -0.05) | 0.02 | 84.8 | < 0.001
PMID:36800965 · one of two readings recorded this
HOMA-IR
no effect, p = 0.98
Unclear | 3 | 0.0 (-0.57, 0.58) | 0.98 | 0 | 0.67
PMID:36800965 · one of two readings recorded this
HOMA-IR
decreases
Decreases were also observed for parameters related to glucose metabolism (FBI and HOMA-IR), Table 5, and.
PMID:36901277 · one of two readings recorded this
HOMA-IR
no effect, n = 24
Fasting glucose, insulin, triglyceride, GLP-1, and calculated insulin resistance (HOMA-IR) did not change significantly within or between treatments (Table 4)
PMID:37513677 · one of two readings recorded this
HOMA-IR
decreases, n = 1065
HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065)
PMID:37598753 · one of two readings recorded this
HOMA-IR
no effect, p = 0.93
homeostatic model assessment for insulin resistance (HOMA-IR) (P = 0.93)
PMID:37605174 · one of two readings recorded this
HOMA-IR
no effect, p = 0.243
The pooled findings indicated no significant decrease in HOMA-IR after consuming low-ratio LA/ALA diet (WMD: 0.09, 95% CI: −0.06, 0.23, p = 0.243)
PMID:37762686 · one of two readings recorded this
HOMA-IR
no effect, p = 0.658
and Asia (WMD: 0.02, 95% CI: −0.15, 0.19, p = 0.658, I2 = 0.0%)
PMID:37762686 · one of two readings recorded this
HOMA-IR
no effect, p = 0.26
among subjects in Europe (WMD: 0.00, 95% CI: −0.42, 0.42, p = 0.260, I2 = 25.8%)
PMID:37762686 · one of two readings recorded this
HOMA-IR
increases, p = 0.012
a significant increase on HOMA-IR among subjects in North America (WMD: 0.47, 95% CI: 0.10, 0.84, p = 0.012, I2 = 0.0%)
PMID:37762686 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0001
the result based on fixed model revealed that resveratrol could remarkably decrease HOMA-IR [SMD = −1.74, 95% CI (−2.24, −1.24), p < 0.0001]
PMID:37767399 · one of two readings recorded this
HOMA-IR
no effect, p = 0.857
SMD = −0.05, 95% CI (−0.55, 0.46), p = 0.857
PMID:37767399 · one of two readings recorded this
HOMA-IR
no effect, p = 0.14
(for HOMA-IR WMD: 0.34; 95%CI: -0.11 to 0.81; P = 0.140)
PMID:37794481 · one of two readings recorded this
HOMA-IR
increases, p = 0.001
Female | 2 | 1.27 (0.58, 1.97) | < 0.001 | 0.289 | 11.2%
PMID:37794481 · one of two readings recorded this
HOMA-IR
no effect, p = 0.301
Male | 2 | 0.34 (-0.31, 1.00) | 0.301 | 0.800 | 0.0% | 0.017
PMID:37794481 · one of two readings recorded this
HOMA-IR
decreases, p = 0.024, n = 46
fasting blood sugar (FBS), insulin (though marginal), and homeostatic model assessment of insulin resistance (HOMA-IR) and more increment in quantitative insulin sensitivity check index (QUICKI; p = 0.014, 0.051, 0.024, and 0.019, respectively)
PMID:37929031 · one of two readings recorded this
HOMA-IR
decreases
HOMA-IR was significantly reduced following vitamin K supplementation compared (WMD: −0⋅24, 95 % confidence interval (CI): −0⋅49, −0⋅02, P = 0⋅047) with placebo
PMID:38282652 · one of two readings recorded this
HOMA-IR
decreases
subgroup analysis showed a significant effect of vitamin K2 supplementation compared to vitamin K1 supplementation on HOMA-IR
PMID:38282652 · one of two readings recorded this
HOMA-IR
decreases, p = 0.002
β - 0.18; 95% CI, - 0.29, - 0.07; P = 0.002
PMID:38294505 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001, n = 34
At the conclusion of the study, BMI (p = 0.0029), HOMA-IR (p < 0.001) significantly decreased, along with decreased numbers of patients with elevated insulin levels
PMID:38295772 · one of two readings recorded this
HOMA-IR
decreases, SMD = -1.56, 95% CI [-2.54, -0.58], p = 0.002, n = 472
The meta-analysis findings support the conclusion that berberine exhibited a potential for reducing HOMA-IR levels (SMD = − 1.56. 95% CI [− 2.54, − 0.58], P = 0.002, I2 = 96%; Fig..
PMID:38429794 · one of two readings recorded this
HOMA-IR
decreases, p = 0.01
cranberry significantly reduced HOMA-IR (MD = −0.59; 95% CI: −1.05, −0.14; peffect = 0.01
PMID:38542695 · one of two readings recorded this
HOMA-IR
no effect, n = 100
However, the HOMA-IR index difference between the four groups was insignificant (all p > 0.05).
PMID:38589346 · one of two readings recorded this
HOMA-IR
decreases, p = 0.00001
quercetin could effectively reduce HOMA-IR (MD=-4.13, 95% CI=[-5.82, -2.44], P < 0.00001)
PMID:38637876 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
the resveratrol group showed a significant reduction in glucose (p = 0.016), insulin (p = 0.001), HOMA-IR (p = 0.001), MDA (p = 0.001), hs-CRP (p = 0.046), TNF-α (p = 0.001), and IL-6 (p = 0.001) compared to the control group
PMID:38790615 · one of two readings recorded this
HOMA-IR
no effect, no statistically significant change in any group
Finally, for insulin resistance, the HOMA-IR index did not show statistically significant differences in any of the three groups.
PMID:39519608 · one of two readings recorded this
HOMA-IR
no effect
The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile
PMID:39531138 · one of two readings recorded this
HOMA-IR
decreases, p = 0.04
(MD: −0.73, 95% CI: −1.44 to −0.02, p = 0.04
PMID:39723101 · one of two readings recorded this
HOMA-IR
decreases, p = 0.05
curcumin had a significant effect on reducing HOMA‐IR (MD: −1.27, 95% CI: −2.53 to −0.01, p = 0.05)
PMID:39723101 · one of two readings recorded this
HOMA-IR
no effect, p = 0.56
(MD: −0.15, 95% CI: −0.65 to 0.36, p = 0.56)
PMID:39723101 · one of two readings recorded this
HOMA-IR
decreases, p = 0.003
HOMA-IR (WMD = -0.91, 95% CI: -1.74 to -0.08, p = 0.003, I2 = 54%)
PMID:39796489 · one of two readings recorded this
HOMA-IR
decreases
(HOMA-IR) (SMD= -0.56; 95 % CI: -0.76, -0.35; P = 0.000, I2 = 84.3 %, P = 0.000)
PMID:40054729 · one of two readings recorded this
HOMA-IR
no effect, p = 0.23, n = 162
HOMA-IR | 5 | 162 | (−1.40, 1.83) | 0.25 | 57.70% (0.00% to 0.82%) | 0.05 | −0.225 (−0.60 to 0.15) | 0.23
PMID:40180416 · one of two readings recorded this
HOMA-IR
no effect, p = 0.226
HOMA‐IR | 1.7 (0.9–2.2) | 2.3 (0.9–3.0) | 0.226 a
PMID:40391740 · one of two readings recorded this
HOMA-IR
decreases
homeostatic model assessment for insulin resistance (HOMA-IR) (WMD: 0.52; 95%CI: 0.84, −0.20; I2 = 82.8%)
PMID:40538540 · one of two readings recorded this
HOMA-IR
decreases
HOMA-IR (WMD: 0.565; 95%CI: 0.779, −0.351; I2 = 0.0%)
PMID:40538540 · one of two readings recorded this
HOMA-IR
decreases, Hedges' g 0.36
However, insulin resistance evaluated with the HOMA-IR showed greater improvements in the MLI+EGCG (Hedge‘effect size of differences of 0.36).
PMID:40664536 · one of two readings recorded this
HOMA-IR
decreases
There was a significant decrease in plasma fasting insulin and HOMA-IR levels in both nanomicelle curcumin capsule and co-supplementation (nanomicelle curcumin capsule + Nigella sativa) versus placebo with a lower amount but higher bioactive form (80 mg/day nanomicelle curcumin)
PMID:40943181 · one of two readings recorded this
HOMA-IR
no effect
changes in homeostasis model assessment of insulin resistance (HOMA-IR) did not reach statistical significance
PMID:40999397 · one of two readings recorded this
HOMA-IR
no effect, p = 0.2
The selenium group intervention failed to significantly reduce insulin resistance in patients compared to the placebo group (P = 0.20, MD = −0.71, 95%CI: −1.80, 0.37)
PMID:41073938 · one of two readings recorded this
HOMA-IR
no effect, p = 0.76
The results showed that selenium supplementation could not significantly reduce the patients’ insulin resistance index (P = 0.76, MD = −0.12, 95% CI: −0.93, 0.69) compared to the placebo group
PMID:41073938 · one of two readings recorded this
HOMA-IR
decreases, p = 0.006
increased to a lesser extent in the probiotic group (∆ = +0.567) compared to the placebo group (∆ = +0.980; p = 0.006)
PMID:41097174 · one of two readings recorded this
HOMA-IR
no effect, p = 0.412
HOMA-IR | 2.5 (1.9, 3.1) | 2.2 (1.5, 2.8) | 0.3 (−0.5, 1.2) | 0.412
PMID:41203981 · one of two readings recorded this
HOMA-IR
increases, p = 0.001
The post-hoc test showed significantly lower in S compared to CT + P (d:—2.39, p < 0.001), and CT (d:—2.42, p < 0.001) groups.
PMID:41249265 · one of two readings recorded this
HOMA-IR
p = 0.001
insulin resistance (F(5,83) = 15.32, p < 0.001, η2 = 0.281)
PMID:41249265 · one of two readings recorded this
HOMA-IR
decreases, p = 0.03
Also, HOMA-IR were significantly lower in CT + S compared with S (d: 2.56, p = 0.030) group.
PMID:41249265 · one of two readings recorded this
HOMA-IR
decreases, SMD = -0.75, 95% CI: -0.96 to -0.53, n = 420
The results indicated that, compared to placebo, mineral supplements significantly reduced HOMA-IR levels in PCOS patients (SMD = -0.75, 95% CI: -0.96 to -0.53, p < 0.001).
PMID:41580698 · one of two readings recorded this
HOMA-IR
decreases, SMD = -0.75, 95% CI: -0.96 to -0.53, p < 0.001, n = 420
The results indicated that, compared to placebo, mineral supplements significantly reduced HOMA-IR levels in PCOS patients (SMD = -0.75, 95% CI: -0.96 to -0.53, p < 0.001).
PMID:41580698 · one of two readings recorded this
HOMA-IR
decreases
The evidence showed a significant reduction in FBG, SMD = -0.22 (-0.39 to -0.05), HbA1c, MD = -1.00%, 95% CI (-1.92 to -0.07), and HOMA-IR, MD = -0.63, 95% CI (-1.20 to -0.06)
PMID:41599883 · one of two readings recorded this
HOMA-IR
decreases
Low doses of vitamin K2 and vitamin K1 were associated with reduced HbA1c and HOMA-IR, respectively
PMID:41599883 · one of two readings recorded this
HOMA-IR
decreases
An intervention of less than 12 weeks was associated with reduced HOMA-IR
PMID:41599883 · one of two readings recorded this
HOMA-IR
decreases
Active vitamin D | -0.45 | (-0.65 to −0.25) | 45%
PMID:41731803 · one of two readings recorded this
HOMA-IR
no effect
Vitamin D2 | -0.15 | (-0.30 to 0.00) | 45%
PMID:41731803 · one of two readings recorded this
HOMA-IR
decreases
HOMA-IR | Vitamin D3 | -0.40 | (-0.60 to −0.20) | 45%
PMID:41731803 · one of two readings recorded this
HOMA-IR
no effect, p = 0.14
HOMA-IR | 2.28 (0.4) | 1.54 (0.2) | 1.45 (0.2) | 1.49 (0.4) |.14
PMID:41866316 · one of two readings recorded this
HOMA-IR
no effect
HOMA-IR (WMD: -0.18, 95% CI: -1.24 to 0.88)
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Age | ≥ 50 years | 2 | 0.39 (-0.81 to 1.58) | 71.4 | 0.061
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
BMI | ≥ 30 kg/m2 | 3 | 0.45 (-1.11 to 2.01) | 81.7 | 0.004
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Dose | 1200 mg | 2 | 0.11 (-2.11 to 2.32) | 88.0 | 0.004
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
≤ 400 mg | 3 | -0.34 (-1.75 to 1.08) | 97.5 | < 0.001
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
≤ 12 weeks | 2 | 0.11 (-2.11 to 2.32) | 88.0 | 0.004
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Follow-up | ≥ 24 weeks | 3 | -0.34 (-1.75 to 1.08) | 97.5 | < 0.001
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
FibroScan | 1 | 1.20 (-0.13 to 2.53) | - | -
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Liver biopsy | 1 | -0.07 (-0.17 to 0.03) | - | -
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Diagnosis of NAFLD | Ultrasonography | 3 | -0.58 (-2.26 to 1.10) | 91.9 | < 0.001
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Sample size | ≥ 50 participants | 3 | -0.34 (-1.75 to 1.08) | 97.5 | < 0.001
PMID:41917882 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
HOMA-IR was significantly reduced in the curcumin group (4.88 [3.49–6.28] vs. 6.71 [5.31–8.11], p < 0.001), also demonstrating a large effect size (r = 0.69, 95% CI: 0.58–0.78)
PMID:42123439 · one of two readings recorded this
HOMA-IR
no effect, p = 0.99
HOMA-IR | 1.4 (1.0–6.2) | 9 | 2.8 (0.0–5.3) | 7 | 0.85 | 2.4 (1.4–6.5) | 9 | 2.4 (0.5–3.2) | 7 | 0.99 | 0.5 ± 0.2 | 0.04 | −0.2 ± 0.4 | 1.00
PMID:42438056 · one of two readings recorded this
HOMA-IR
decreases, WMD -0.48, 95% CI -0.79 to -0.18
The pooled analysis revealed that Mg supplementation significantly reduced HOMA-IR (WMD: −0.48, 95% CI: −0.79, −0.18), serum HbA1c (WMD: −0.15%, 95% CI: −0.26, −0.03), and FBG (WMD: −3.60 mg/dL, 95% CI: −6.13, −1.06) in comparison with the placebo group.
PMID:42588058 · one of two readings recorded this
HOMA-IR
decreases, p = 0.02
(MD = −1.10; 95% CI −2.05 to −0.15; p = 0.02)
PMID:42594341 · one of two readings recorded this
HOMA-IR
no effect, p = 0.31
Four studies showed no significant differences (MD = −0.75; 95% CI −2.20 to 0.69; p = 0.31
PMID:42594341 · one of two readings recorded this
HOMA-IR
decreases, p = 0.007
Three studies showed significant reductions (MD = −1.49; 95% CI −2.57 to −0.41; p = 0.007
PMID:42594341 · one of two readings recorded this
Sources cited
33 papers
- Subject
- homa-ir
- Findings
- 33
- Papers
- 33
Bisphenol A decreases peripheral insulin sensitivity in normal weight adults: a double-blind randomized controlled trial.record2026PMID:418663161 finding
Effect of Sucralose Consumption on Gut Microbiota: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:427948021 finding
Effects of Zinc Supplementation on Glycemic Control, Insulin Resistance, Inflammation and Oxidative Stress in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2026PMID:425943411 finding
Gut microbiota-generated trimethylamine N-oxide from dietary choline and glucose homeostasis in humans.record2026PMID:423147691 finding
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.record2025PMID:401804161 finding
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.record2025PMID:415152491 finding
Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2025PMID:408856031 finding
Effects of L-Citrulline Supplementation on Endothelial Function, Arterial Stiffness, and Blood Glucose Level in the Fasted and Acute Hyperglycemic States in Middle-Aged and Older Adults with Type 2 Diabetes.record2025PMID:413740291 finding
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.record2025PMID:412540271 finding
Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis.record2024PMID:386378761 finding
The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.record2024PMID:387556221 finding
Effect of vitamin E intake on glycemic control and insulin resistance in diabetic patients: an updated systematic review and meta-analysis of randomized controlled trials.record2023PMID:368009651 finding
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2023PMID:375987531 finding
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.record2023PMID:364822581 finding
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.record2022PMID:361597921 finding
Moringa oleifera Improves MAFLD by Inducing Epigenetic Modifications.record2022PMID:362969071 finding
Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.record2022PMID:352773981 finding
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.record2022PMID:363130961 finding
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.record2021PMID:349614181 finding
Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2021PMID:344964121 finding
The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women.record2021PMID:345288711 finding
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2021PMID:349564361 finding
The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis.record2021PMID:339884781 finding
Effects of l-arginine supplementation on glycemic profile: Evidence from a systematic review and meta-analysis of clinical trials.record2020PMID:325613571 finding
Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner.record2020PMID:325792921 finding
Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials.record2018PMID:289335781 finding
Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress.record2018PMID:306625841 finding
The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.record2018PMID:304177821 finding
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.record2014PMID:252618821 finding
Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials.record2014PMID:246958901 finding
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.record2013PMID:229304031 finding
Curcumin extract for prevention of type 2 diabetes.record2012PMID:227737021 finding
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.record2011PMID:206341741 finding